Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
Yi‐Chou Hou, Cai‐Mei Zheng, Tzung‐Hai Yen, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 7833-7833
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Insulin resistance and cardiovascular disease
Constantine E. Kosmas, Maria D. Bousvarou, Christina Kostara, et al.
Journal of International Medical Research (2023) Vol. 51, Iss. 3
Open Access | Times Cited: 127
Direct cardiac effects of SGLT2 inhibitors
Sha Chen, Ruben Coronel, Markus W. Hollmann, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 107
Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
Maria Rosaria Rizzo, Irene Di Meo, Rita Polito, et al.
Pharmacological Research (2022) Vol. 176, pp. 106062-106062
Open Access | Times Cited: 105
Applications of SGLT2 inhibitors beyond glycaemic control
Daniel V. O’Hara, Carolyn S.P. Lam, John J.V. McMurray, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 8, pp. 513-529
Closed Access | Times Cited: 24
New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy
Giovanna Gallo, Oreste Lanza, Carmine Savoia
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5089-5089
Open Access | Times Cited: 28
Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management
Aroob Fatima, Sohaib Rasool, S. Sindu Devi, et al.
Cureus (2023)
Open Access | Times Cited: 28
Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis
Shimaa K. Elkazzaz, Dina M. Khodeer, Hassan M. El Fayoumi, et al.
Life Sciences (2021) Vol. 280, pp. 119018-119018
Closed Access | Times Cited: 45
SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review
Daria M. Keller, Natasha Ahmed, Hamza Tariq, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 6, pp. 1470-1470
Open Access | Times Cited: 33
Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy
Yong-Ping Lu, Hongwei Wu, Ting Zhu, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113947-113947
Open Access | Times Cited: 32
Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study
Kristina Charaya, Dmitry Shchekochikhin, Д. А. Андреев, et al.
Open Heart (2022) Vol. 9, Iss. 1, pp. e001936-e001936
Open Access | Times Cited: 31
Relevance of Sugar Transport across the Cell Membrane
Roxana Carbó, Emma Rodrı́guez
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6085-6085
Open Access | Times Cited: 18
Updates on New Therapies for Patients with CKD
Tushar Tarun, Sai Nikhila Ghanta, Vincz Ong, et al.
Kidney International Reports (2023) Vol. 9, Iss. 1, pp. 16-28
Open Access | Times Cited: 16
Management of chronic kidney disease: The current novel and forgotten therapies
Ákos Pethő, Mihály Tapolyai, Éva Csongrádi, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100354-100354
Open Access | Times Cited: 7
SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits
Giovanna Leoncini, Elisa Russo, Elisabetta Bussalino, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4441-4441
Open Access | Times Cited: 36
Impact of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging—What Do We Know So Far? (A Narrative Review)
Cristina Andreea Adam, Răzvan Anghel, Dragoș Traian Marius Marcu, et al.
Life (2022) Vol. 12, Iss. 6, pp. 803-803
Open Access | Times Cited: 27
Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
Peter Kolkhof, Robert Lawatscheck, Gerasimos Filippatos, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9243-9243
Open Access | Times Cited: 26
Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation
Reem M. Hazem, Ahmed Z. Ibrahim, Dina A. Ali, et al.
International Immunopharmacology (2022) Vol. 104, pp. 108503-108503
Closed Access | Times Cited: 23
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial
Soo Heon Kwak, Kyung Ah Han, Kyung‐Soo Kim, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 7, pp. 1865-1873
Open Access | Times Cited: 14
Megalin knockout reduces SGLT2 expression and sensitizes to Western diet-induced kidney injury
Elynna B. Youm, Katherine E. Shipman, Wafaa N. Albalawy, et al.
Function (2024) Vol. 5, Iss. 4
Open Access | Times Cited: 5
Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease
Suyan Duan, Lu Fang, Dandan Song, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 29
Insulin Resistance and High Blood Pressure: Mechanistic Insight on the Role of the Kidney
Gabriele Brosolo, Andrea Da Porto, Luca Bulfone, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2374-2374
Open Access | Times Cited: 21
Mutual Regulation between Redox and Hypoxia-Inducible Factors in Cardiovascular and Renal Complications of Diabetes
Carla Iacobini, Martina Vitale, Jonida Haxhi, et al.
Antioxidants (2022) Vol. 11, Iss. 11, pp. 2183-2183
Open Access | Times Cited: 20
SGLT2 inhibitors in peritoneal dialysis: a promising frontier toward improved patient outcomes
N. Stepanova
Renal Replacement Therapy (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 4
Effects of dapagliflozin on heart rate variability, cardiac function, and short-term prognosis in early-onset post-myocardial infarction heart failure
Le Zhou, Mingyuan Niu, Wei J. Chen, et al.
Frontiers in Cardiovascular Medicine (2025) Vol. 11
Open Access
Analysis of the Endocrine Responses to Anti-Diabetes Drugs: An Issue of Elevated Plasma Renin Concentration in Sodium-Glucose Co-Transporter 2 Inhibitor
Cheng-Wei Lin, Shih‐Yuan Hung, I-Wen Chen
International Journal of General Medicine (2025) Vol. Volume 18, pp. 135-144
Open Access
Page 1 - Next Page

Scroll to top